SCHEMBL23218478

SCHEMBL23218478

CCOC(=O)C(C(=O)C(C)C)c1cc(Cl)cc(Br)c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.38
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GPR35 Q9HC97 1/20 0.35
PARP1 P09874 1/20 0.35
PARG Q86W56 1/20 0.35
ERN1 O75460 1/20 0.35
THRB P10828 1/20 0.35
PTP4A1 Q93096 1/20 0.34
MAPT P10636 5/20 0.34
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
APAF1 O14727 1/20 0.34
NPC1 O15118 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218269 0.86 MAOB (0.39) MAOBGABRA1GABRB1GPR35ERN1
SCHEMBL29592028 0.79 MAOB (0.35) MAOBGPR35THRBMAPTALDH1A1
SCHEMBL23218699 0.79 MAOB (0.35) MAOBGPR35THRBMAPTALDH1A1
SCHEMBL8334701 0.75 GAA (0.39) MAOBGABRA1GABRB1GPR35ERN1
SCHEMBL27819219 0.74 GABRA1 (0.47) MAOBGABRA1GABRB1PARP1PARG
SCHEMBL23218343 0.71 GAA (0.45) MAOBERN1PTP4A1MAPTMEN1
SCHEMBL27485527 0.69 GABRA1 (0.46) MAOBGABRA1GABRB1PARP1PARG
SCHEMBL5720943 0.69 ESR1 (0.37) MAOBGABRA1GABRB1GPR35PARP1
SCHEMBL2978694 0.68 GABRA1 (0.52) GABRA1GABRB1PARP1PARGERN1
SCHEMBL8325179 0.68 GAA (0.39) THRBMAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885GABRA1 3792/4885GABRB1 3695/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885GABRA1 4487/4885GABRB1 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.